'Scent device' could help detect bladder cancer

July 8, 2013, University of Liverpool

Researchers from the University of Liverpool and University of the West of England, (UWE Bristol), have built a device that can read odours in urine to help diagnose patients with early signs of bladder cancer.

There are currently no reliable to screen patients for bladder cancer in the same way that there are for breast and cervical cancers. Previous research has suggested that a particular in the urine could be detected by dogs trained to recognise the scent, indicating that methods of diagnoses could be based on the smell of certain .

The team have now built a device, called ODOREADER that contains a sensor which responds to chemicals in gas emitted from urine. The device, constructed in the laboratories at UWE Bristol's Institute of Biosensor Technology, analyses this gas and produces a 'profile' of the chemicals in urine that can be read by scientists to diagnose the presence of cancer cells in the bladder.

Professor Chris Probert, from the University of Liverpool's Institute of Translational Medicine, explains: "Each year approximately 10,000 people in the UK are diagnosed with bladder cancer. It is a disease that, if caught early, can be treated effectively, but unfortunately we do not have any early other than diagnosis through at the stage when it starts to become a problem."

The device works by inserting a bottle containing the into the device. About 30 minutes later the ODOREADER is capable of showing the diagnosis on the if the sample derives from a patient with bladder cancer.

Professor Norman Ratcliffe, from the Institute of Biosensor Technology at UWE Bristol, said: "It is thought that dogs can smell cancer, but this is obviously not a practical way for hospitals to diagnose the disease. Taking this principle, however, we have developed a device that can give us a profile of the odour in urine. It reads the gases that chemicals in the urine can give off when the sample is heated."

Professor Probert added: "We looked at 98 samples of urine to develop the device, and tested it on 24 patient samples known to have cancer and 74 samples that have urological symptoms, but no cancer. The device correctly assigned 100% of cancer patients.

"Bladder cancer is said to be the most expensive cancer to treat, due to repeated scopes to inspect the development of the in the bladder. ODOREADER has the potential to dramatically cut these costs by preventing scopes.

"These results are very encouraging for the development of new diagnostic tools for bladder cancer, but we now need to look at larger samples of patients to test the device further before it can be used in hospitals."

Explore further: 700 women with urinary cancers in England missing out on prompt diagnosis every year

More information: The work, also in collaboration with Bristol Urological Institute, is published in the journal PLOS ONE.

Related Stories

700 women with urinary cancers in England missing out on prompt diagnosis every year

June 24, 2013
Around 700 women in England with symptoms of kidney or bladder cancer are missing out on prompt diagnosis and treatment of their condition every year, reveals research in the online only journal BMJ Open.

Key find for early bladder cancer treatment

May 23, 2013
Aggressive forms of bladder cancer involve the protein PODXL – a discovery that could hold the key to improved treatment, according to researchers at Lund University, Uppsala University and KTH in Sweden.

Bladder cancer recurrence and mortality could decline with better treatment compliance

June 5, 2013
(Medical Xpress)—Researchers at UCLA's Jonsson Comprehensive Cancer Center led by Dr. Karim Chamie have found that more intense surveillance and treatment of bladder cancer in the first two years after diagnosis could reduce ...

Multi-tasking imatinib boosts radiotherapy for bladder tumours

March 4, 2013
Cancer drug imatinib (Glivec) could boost radiotherapy treatment to destroy bladder cancer that has spread to the bladder wall, reveals research published in Cancer Research.

Genetic alterations linked with bladder cancer risk, recurrence, progression, and patient survival

March 25, 2013
A new analysis has found that genetic alterations in a particular cellular pathway are linked with bladder cancer risk, recurrence, disease progression, and patient survival. Published early online in Cancer, a peer- reviewed ...

Recommended for you

'Kiss of death' cancer: How computational geeks may have uncovered a therapy for a deadly disease

June 19, 2018
It's called the 'kiss of death'. Triple negative breast cancer has no targeted drug therapy and, as such, the only hope for these patients is chemotherapy. Triple negative breast cancer is aggressive and deadly. Patients ...

Ovarian cancer cells switched off by 'unusual' mechanism

June 19, 2018
Scientists at the Ovarian Cancer Action Research Centre at Imperial College London have discovered a mechanism that deactivates ovarian cancer cells.

Team discovers gene mutations linked to pancreatic cancer

June 19, 2018
Six genes contain mutations that may be passed down in families, substantially increasing a person's risk for pancreatic cancer. That's according to Mayo Clinic research published in the June 19 edition of the JAMA. However, ...

Breast cancer could be prevented by targeting epigenetic proteins, study suggests

June 19, 2018
Researchers at the Princess Margaret Cancer Centre in Toronto have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone. The study, which will ...

Targeting the engine room of the cancer cell

June 18, 2018
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug ...

Study suggests well-known growth suppressor actually fuels lethal brain cancers

June 18, 2018
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.